title: Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use.
authors.forename: M
authors.initials: M
authors.lastname: Kuloglu
authors.forename: A
authors.initials: A
authors.lastname: Caykoylu
authors.forename: O
authors.initials: O
authors.lastname: Ekinci
authors.forename: D
authors.initials: D
authors.lastname: Bayindirli
authors.forename: G
authors.initials: G
authors.lastname: Vural
authors.forename: O
authors.initials: O
authors.lastname: Deniz
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D017374:Paroxetine / Q000009:adverse effects*; D011569:Psychiatric Status Rating Scales; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D018687:Antidepressive Agents, Second-Generation; D009025:Morpholines; D017374:Paroxetine; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors